CDA | Evidence Driven
CDA | Evidence Driven

relugolix, estradiol, and norethindrone acetate

Details

Generic Name:
relugolix, estradiol, and norethindrone acetate
Project Status:
Pending
Therapeutic Area:
Management of heavy menstrual bleeding associated with uterine fibroids
Manufacturer:
Pfizer Canada ULC and Sumitomo Pharma Switzerland GmbH
Call for patient/clinician input open:
Brand Name:
Myfembree
Project Line:
Reimbursement Review
Project Number:
SR0885-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​​Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : December 16, 2024